Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Agur unpublished OBSmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
-/- no results
    Aleman DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
    -/- no results
      Benotmane DESCSpikevax (Moderna mRNA-1273 COVID-19 vaccine)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
      -/- no results
        Boyarsky DESCmRNA vaccineuncontrolled studyCOVID-19 prophylaxis (excluding children)NA
        -/- no results
          Palich DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
          -/- no results
            Rozen-Zvi DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
            -/- no results
              Yanay DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
              -/- no results
                Zadok DESCComirnaty (tozinameran - Pfizer/BIONTECH)uncontrolled studyCOVID-19 prophylaxis (excluding children)NA
                -/- no results

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).